ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q3Scopus Q2SCImago #6,914Hybrid

Oncotargets and Therapy

Abbreviation (ISO):ONCOTARGETS THER
•
Identifier (ISSN):1178-6930(Print)
•
Publisher:Dove Medical Press Ltd.
Clarivate IF (2026)
2.4↓ -0.4
Journal Impact Factor
IF Trend↓
WoS Quartile
Q3
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Oncotargets and Therapy

WoS Q3
13462.6620183.0520193.3420204.1520214.342022420232.720242.820252.42026
Annual Impact Factor Metric
Current (2026):2.4
Scopus SJR & RankScopus Q2
0.8
#6,914

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
100

100 papers with at least that number of citations each

WoS: SCIE / JCRQ3
Self-Citation Rate0%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
448articles/year
98.47% Gold OA•63.71% Original Research

Aims & Scope

OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.

Topics Covered (Recognized by AI)
MedicineBiologyGeneticsInternal MedicineChemistryOncology & Cancer ResearchBiochemistryCancer ResearchPathologyOncologyImmunologySurgeryCell BiologyMathematics

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Q3
Rank122/180
IndexSCIE
JCRSCIE2026

ONCOLOGY

Q3
Rank214/333
IndexSCIE
JCISCIE2026

BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Q3
Rank133/180
IndexSCIE
JCISCIE2026

ONCOLOGY

Q3
Rank241/333
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF2.4
Articles / Year77
Total Citations14
2025
IF2.8
Articles / Year104
Total Citations265
2024
IF2.7
Articles / Year142
Total Citations386
2023
IF4
Articles / Year146
Total Citations619
2022
IF4.345
Articles / Year191
Total Citations1,576

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #6,914Scopus Q2SCImago Profile
Scopus Coverage:2009-2026
Scopus Broad Areas:Medicine
Scopus Citation Rank (SJR)Q2
0.8

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2
Citations / Doc (2 years)
2.34

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,206 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations795
3-Year Documents297
Citable Documents292

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate45.3%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

OncologyQ2
Pharmacology (medical)Q2
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
3区 (Zone 3)Medicine
Minor Category (Specific Field):
3区BIOTECHNOLOGY & APPLIED MICROBIOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
In warning list
2021
In warning list
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Oncotargets and Therapy (abbr: ONCOTARGETS THER, ISSN: 1178-6930) is a peer-reviewed international scholarly journal in the field of BIOTECHNOLOGY & APPLIED MICROBIOLOGY, published by Dove Medical Press Ltd. in England since 2008. The periodical holds a Journal Impact Factor (JIF) of 2.40, ranking in quartile Q3 of Web of Science (SCIE), a Scopus SJR indicator of 0.800 (Q2), an H-index of 100.

The journal enforces rigorous peer evaluation with an annual output of approximately 448 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,206 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Dove Medical Press Ltd.
Publication Language
English
Frequency
Periodic
Founding Year
2008
Indexing & Databases
SCIEScopusDOAJPubMed
Editorial Address
PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 11bfa125-f8e2-412c-a307-23a36d33c4f9
Database Updated: 2026-09-28